"Our whole approach is based on the idea that science matters at the FDA"
December 28, 2008 8:50 AM Subscribe
The Economist on Drugs -- Scientists in North America, Europe and Israel are studying the use of MDMA, LSD, hallucinogenic mushrooms, marijuana and other banned psychoactive substances in treating conditions such as anxiety, cluster headaches, addiction and obsessive-compulsive disorder. They are supported by private funds from a handful of organisations: the Beckley Foundation in Britain; the Heffter Research Institute and the Multidisciplinary Association for Psychedelic Studies (MAPS) in America. [related]
This thread has been archived and is closed to new comments